Acute Myeloid Leukemia (non-APL) · line 1 · 7+3 + quizartinib induction + maintenance for FLT3-ITD+ AML 1L
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-QUIZARTINIB-7-3 |
| ID | IND-AML-1L-QUIZARTINIB-FLT3ITD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-AML |
| Sources | SRC-ELN-AML-2022 SRC-NCCN-AML-2025 SRC-QUANTUM-FIRST-ERBA-2023 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 1L for FLT3-ITD+ AML age 18-75 fit. Replaces midostaurin pathway for ITD-dominant disease. AlloHCT in CR1 still considered for high-risk subset. Ukraine access barrier (not registered) drives practical 1L still toward midostaurin (also unfunded) or intensive 7+3 alone.
Used By
Algorithms
ALGO-AML-2L- ALGO-AML-2L